Document is current

Article History

Received: 9 January 2022

Accepted: 16 May 2022

First Online: 4 June 2022

Declarations

:

: For TRIAD, all participants have provided written informed consent and the study has been approved by McGill University Institutional Review Board. The Ethics Committee at the University of Gothenburg has approved the use of the plasma samples (EPN 140811).

: Not applicable

: HZ has served at scientific advisory boards and/or as a consultant for Abbvie, Alector, Annexon, AZTherapies, CogRx, Denali, Eisai, Nervgen, Pinteon Therapeutics, Red Abbey Labs, Roche, Samumed, Siemens Healthineers, Triplet Therapeutics, and Wave; has given lectures in symposia sponsored by Cellectricon, Fujirebio, Alzecure, and Biogen; and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program. KB has served as a consultant, at advisory boards, or at data monitoring committees for Abcam, Axon, Biogen, JOMDD/Shimadzu, Julius Clinical, Lilly, MagQu, Novartis, Roche Diagnostics, and Siemens Healthineers and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program. MM is an employee of Quanterix Corporation, Lexington, Massachusetts. AJ is an advisor for Quanterix Corporation, Lexington, Massachusetts. The other authors declare no competing interests.